Association of fibroblast growth factor 21 with metabolic phenotype and fat depots in young adults with abdominal obesity
- Authors: Zheleznova E.A.1, Zhernakova J.V.1, Shariia M.A.1, Blinova N.V.1, Azimova M.O.1, Sharf T.V.1, Masenko V.P.1, Chazova I.E.1
-
Affiliations:
- National Medical Research Center for Cardiology
- Issue: Vol 22, No 12 (2020)
- Pages: 23-30
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95354
- DOI: https://doi.org/10.26442/20751753.2020.12.200560
- ID: 95354
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina A. Zheleznova
National Medical Research Center for Cardiology
Email: katia.zheleznova@yandex.ru
преподаватель каф. кардиологии с курсом интервенционных методов диагностики и лечения Moscow, Russia
Juliya V. Zhernakova
National Medical Research Center for Cardiologyд-р мед. наук, ученый секретарь Moscow, Russia
Merab A. Shariia
National Medical Research Center for Cardiologyд-р мед. наук, вед. науч. сотр. отд. томографии Moscow, Russia
Nataliia V. Blinova
National Medical Research Center for Cardiologyканд. мед. наук, науч. сотр. отд. гипертонии Moscow, Russia
Marina O. Azimova
National Medical Research Center for Cardiologyаспирант отд. гипертонии Moscow, Russia
Tatiana V. Sharf
National Medical Research Center for Cardiologyнауч. сотр. лаб. иммунохимии Moscow, Russia
Valerii P. Masenko
National Medical Research Center for Cardiologyгл. науч. сотр., рук. лаб. нейрогуморальной регуляции Moscow, Russia
Irina E. Chazova
National Medical Research Center for Cardiologyакад. РАН, д-р мед. наук, проф., зам. ген. дир. по научно-экспертной работе Moscow, Russia
References
- Choi JR et al. Serum fibroblast growth factor 21 and new-onset metabolic syndrome: KoGES-ARI-RANG study. Yonsei Med J 2018; 59 (2): 287-93. doi: 10.3349/ymj.2018.59.2.287
- Wang YS et al. Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: A systematic review and meta-analysis. Postgrad Med J 2019; 95 (1121). doi: 10.1136/postgrad-medj-2018-136002
- Staiger H, Keuper M, Berti L et al. Fibroblast growth factor 21 -metabolic role in mice and men. Endocrine Rev 2017; 38 (5): 468-88. doi: 10.1210/er.2017-00016
- Hong ES et al. Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes. BMJ Open Diabetes Res Care 2019; 7 (1). doi: 10.1136/bmjdrc-2019-000776
- Bobbert T et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 2013; 36 (1): 145-9. doi: 10.2337/dc12-0703
- Chen C et al. High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: A 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011; 34 (9): 2113-5. doi: 10.2337/dc11-0294
- Zhang X et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57 (5): 1246-53. doi: 10.2337/db07-1476
- Tan BK, Hallschmid M, Adya R et al. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: Relationship with plasma FGF21 and body adiposity. Diabetes 2011; 60 (11): 2758-62. doi: 10.2337/db11-0672
- Akyildiz ZI et al. Epicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal women. J Endocrinol Invest 2015; 38 (3): 361-6. doi: 10.1007/s40618-014-0185-3
- Giannini C et al. Circulating levels of FGF-21 in obese youth: Associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab 2013; 98 (7): 2993-3000. doi: 10.1210/jc.2013-1250
- Domouzoglou EM et al. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Hear Circ Physiol 2015; 309: 1029-38. doi: 10.1152/ajpheart.00527.2015
- Lakhani I et al. Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis. Metabolism 2018; 83: 11-7. doi: 10.1016/j.metabol.2018.01.017
- Zhang W, Chu S, Ding W, Wang F Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction. PLoS One 2015; 10 (6). doi: 10.1371/journal.pone.0129791
- Xu P et al. Efficacy of a combination of high and low dosage of PEGylated FGF-21 in treatment of diabetes in db/db mice. Biomed Pharmacother 2016; 84: 97-105. doi: 10.1016/j.biopha.2016.09.019
- Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol Nat Res 2020. doi: 10.1038/s41574-020-0386-0
- Ritchie M, Hanouneh IA, Noureddin M et al. Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? Exp Opin Investig Drugs 2020; 29 (2): 197-204. doi: 10.1080/13543784.2020.1718104
- Ye X et al. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes. J Diabetes Complications 2017; 31 (4): 726-34. doi: 10.1016/j.jdia-comp.2017.01.008
- Ross R et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol 2020; 16 (3): 177-89. doi: 10.1038/s41574-019-0310-7
- Fisher FM et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59 (11): 2781-9. doi: 10.2337/db10-0193
- Hollstein T, Piaggi P Metabolic Factors Determining the Susceptibility to Weight Gain: Current Evidence. Curr Obesity Rep 2020; 9: 121-35. doi: 10.1007/s13679-020-00371-4
- Markan KR. Defining ‘FGF21 Resistance’ during obesity: Controversy, criteria and unresolved questions version 1; referees: 1 approved, 2 approved with reservations. F1000Res 2018; 7. doi: 10.12688/f1000research.14117.1
- Tanajak P Letter to the editor: Parameters, characteristics, and criteria for defining the term ‘fGF21 resistance. Endocrinology 2017; 158 (5): 1523-4. doi: 10.1210/en.2017-00056
- Britton KA et al. Prevalence, distribution, and risk factor correlates of high thoracic periaortic fat in the Framingham Heart Study. J Am Heart Assoc 2012; 1 (6). doi: 10.1161/JAHA.112.004200
- Sarin S et al. Clinical Significance of Epicardial Fat Measured Using Cardiac Multislice Computed Tomography. Am J Cardiol 2008; 102 (6): 767-71. doi: 10.1016/j.amjcard.2008.04.058
- Zhang X et al. Erratum: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2019; 68 (1): 235. doi: 10.2337/db19-er01 c
- Shen Y et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 2013; 12 (1). doi: 10.1186/1475-2840-12-124
- Lee Y et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf) 2014; 80 (1): 57-64. doi: 10.1111/cen.12134
- Shafaei Y, Khoshnia M, Marjani A. Serum level of fibroblast growth factor 21 in type 2 diabetic patients with and without metabolic syndrome. J Med Sci 2015; 15 (2): 80-6. doi: 10.3923/jms.2015.80.86
- Asrih M, Veyrat-Durebex C, Poher AL et al. Leptin as a potential regulator of FGF21. Cell Physiol Biochem 2016; 38 (3): 1218-25. doi: 10.1159/000443070
- Hanks LJ, Gutierrez OM, Bamman MM et al. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J Clin Transl Endocrinol 2015; 2 (2): 77-82. doi: 10.1016/j.jcte.2015.02.001
- Matsui M et al. Relationship between physical activity and circulating fibroblast growth factor 21 in middle-aged and older adults. Exp Gerontol 2020; 141: 111081. doi: 10.1016/j.exger.2020.111081
- Woo YC et al. Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes. Clin Endocrinol 2017; 86 (1): 37-43. doi: 10.1111/cen.13229
- Li G et al. FGF21 deficiency is associated with childhood obesity, insulin resistance and hypoadipo-nectinaemia: The BCAMS Study. Diabetes Metab 2017; 43 (3): 253-60. doi: 10.1016/j.dia-bet.2016.12.003
- An SY et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 2012; 96 (2): 196-203. doi: 10.1016/j.diabres.2012.01.004
- Ferreira JP et al. Circulating plasma proteins and new-onset diabetes in a population-based study: Proteomic and genomic insights from the STANISLAS cohort. Eur J Endocrinol 2020; 183 (3): 28595. doi: 10.1530/EJE-20-0246
- Lundsgaard AM et al. Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates. Mol Metab 2017; 6 (1): 22-9. doi: 10.1016/j.molmet.2016.11.001
- Dushay JR, Toschi E, Mitten EK et al. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab 2015; 4 (1): 51-7. doi: 10.1016/j.molmet.2014.09.008
- Laeger T et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest 2014; 124 (9): 3913 22. doi: 10.1172/JCI74915
- Soberg S et al. FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans. Cell Metab 2017; 25 (5): 1045-53.e6. doi: 10.1016/j.cmet.2017.04.009